Search the Newsreel

Weilong’s first-half profit ticks up 4% as signature spicy strip sales fall

Elicio Therapeutics (NASDAQ:ELTX) Announces Earnings Results

Elicio Therapeutics (NASDAQ:ELTX) announced its quarterly earnings, reporting a loss of $0.43 per share, which surpassed analyst estimates by $0.11. Despite a 2.9% rise in shares following the announcement, the stock remains significantly below its 52-week high, with a market capitalization of $60.1 million. …

Elicio Therapeutics (ELTX) faces going-concern risk after $20M loss and trial miss

Elicio Therapeutics reported a net loss of $20.0 million for the first half of 2026 and faces substantial doubt about its ability to continue as a going concern, with existing cash expected to fund operations only into Q1 2027. The company's lead Phase 2 …

Elicio Therapeutics: Q2 Earnings Snapshot

Elicio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Elicio Therapeutics announced its second-quarter 2026 financial results and provided corporate updates, including plans to initiate a Phase 1 combination study of ELI-002 7P for metastatic pancreatic cancer in Q4 2026, following observations of multiple complete responses. While its Phase 2 AMPLIFY-7P trial did …

WL Delicious Announces 2026 Interim Results：Rooted in Consumer Needs, Steadily Advancing its Delicious and Healthy Strategy，Interim Payout Ratio Significantly Raised to 90%

Weilong Sets 2026–2028 Dividend Framework to Boost Predictable Shareholder Returns

Weilong Delicious Delivers Higher Interim Revenue, Margins and Dividends

Weilong Delicious Declares Interim Cash Dividend for First Half of 2026

Weilong Delicious Announces Special Mid-Year Cash Dividend

Global Vectra Helicorp net loss widens to ₹1,184.81 lakh in Q1FY27

Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma

Elicio Therapeutics has announced the activation of an investigator-initiated Phase 1 study for its immunotherapy ELI-002 7P, targeting KRAS-driven pancreatic ductal adenocarcinoma (PDAC) in the neoadjuvant setting. The study, conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation and Break …

Elicio Study to Test Immunotherapy Before Pancreatic Cancer Surgery

Elicio Therapeutics has activated an investigator-initiated Phase 1 study to evaluate its immunotherapy ELI-002 7P in patients with resectable and borderline resectable KRAS-mutant pancreatic ductal adenocarcinoma (PDAC). The study, conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation and Break …

Helical PLC Buys Back 200,000 Shares for Treasury Under Ongoing Programme

Global Vectra Helicorp Ltd is Rated Strong Sell

Certain Warrants of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026.

Elicio Therapeutics, Inc. has certain warrants under a lock-up agreement that ends on August 6, 2026. The lock-up period for these warrants began on July 6, 2026, and lasts for 31 days. This agreement restricts officers and directors from selling or disposing of common …

Price to book forward of Global Vectra Helicorp Limited – NSE:GLOBALVECT

Helical plc (HLCL) Reports 116,095,589 Total Voting Rights as of 31 July 2026

Elicio Therapeutics, Inc. (NASDAQ:ELTX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Elicio Therapeutics (ELTX) Expected to Post Earnings on Thursday

InteliCare Holdings Swings to $384K Operating Cash Flow in June Quarter as Deployment Gains Traction

Elicio Therapeutics Inc (ELTX) Institutional Confidence

The article reports on Elicio Therapeutics Inc.'s (ELTX) institutional confidence score, which stands at 3.00, placing it 192nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 37.43% quarter-over-quarter, reaching 15.12%. James Simons is noted as the …

Price to sales ratio of Elicio Therapeutics, Inc – HAM:9HA

This article provides financial information for Elicio Therapeutics, Inc (HAM:9HA), specifically focusing on its price to sales ratio. The content lists the company's trading information on the Hamburg Stock Exchange and indicates that no trades have occurred for the period. It also details the …

Elicio Therapeutics Inc (ELTX) Cash Flow

This article provides a detailed cash flow statement for Elicio Therapeutics Inc (ELTX), including quarterly and annual data for operating, investing, and financing activities. It presents financial figures such as net income, capital expenditures, and changes in working capital across multiple fiscal years. The …

Working capital per share of Elicio Therapeutics, Inc – HAM:9HA

This article provides working capital per share data for Elicio Therapeutics, Inc (HAM:9HA) on the Hamburg Stock Exchange. The market was closed at the time of publication, with no trades recorded. The content is presented as part of TradingView's financial data offerings.

InteliCare Expands Hardi Aged Care Partnership With 84-Bed Facility Upgrade and Multi-Site Nurse Call Rollout

InteliCare (ASX:ICR) Unlocks Further Growth Opportunity With Expanded Hardi Aged Care Rollout

Elicio Therapeutics Inc (ELTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown of Elicio Therapeutics Inc (ELTX). It states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page provides current stock information for ELTX, including its market cap …

Elicio Therapeutics Inc (ELTX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Elicio Therapeutics Inc (ELTX) shareholder structure, listing major shareholders and institutional holdings. It highlights key entities like GKCC, LLC and Knoll Capital Management, LLC, their proportions, and also categorized shareholder types. The report also tracks changes in …

ELTX|Elicio Therapeutics Inc|Price:3.000|Chg%:-0.150

Elicio Therapeutics Inc (ELTX) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, specifically targeting mutant KRAS, BRAF, and TP53. Despite a recent weak market performance, the company exhibits strong fundamentals and technicals and is considered fairly valued. Analysts have given it …

Elicio Therapeutics, Inc. Revenue Breakdown – NASDAQ:ELTX

The article discusses the revenue breakdown of Elicio Therapeutics Inc (ELTX). It states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page provides current stock information for ELTX, including its market cap …

Form 4 Elicio Therapeutics Inc For: 17 July By Investing.com

This Investing.com article reports on a Form 4 filing for Elicio Therapeutics Inc. on July 17. The Form 4 is a U.S. Securities and Exchange Commission document used to report changes in beneficial ownership of a company's stock by insiders. The article indicates that …